TWIST BIOSCIENCE CORP (TWST) Stock Fundamental Analysis

NASDAQ:TWST • US90184D1000

48.09 USD
-0.5 (-1.03%)
At close: Feb 23, 2026
47.65 USD
-0.44 (-0.91%)
After Hours: 2/23/2026, 7:13:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, TWST scores 4 out of 10 in our fundamental rating. TWST was compared to 521 industry peers in the Biotechnology industry. TWST has a great financial health rating, but its profitability evaluates not so good. TWST is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year TWST has reported negative net income.
  • In the past year TWST has reported a negative cash flow from operations.
  • In the past 5 years TWST always reported negative net income.
  • TWST had a negative operating cash flow in each of the past 5 years.
TWST Yearly Net Income VS EBIT VS OCF VS FCFTWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • TWST's Return On Assets of -12.00% is amongst the best of the industry. TWST outperforms 83.11% of its industry peers.
  • With an excellent Return On Equity value of -16.79%, TWST belongs to the best of the industry, outperforming 85.60% of the companies in the same industry.
Industry RankSector Rank
ROA -12%
ROE -16.79%
ROIC N/A
ROA(3y)-24.14%
ROA(5y)-23.35%
ROE(3y)-31.13%
ROE(5y)-29.44%
ROIC(3y)N/A
ROIC(5y)N/A
TWST Yearly ROA, ROE, ROICTWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

1.3 Margins

  • The Gross Margin of TWST (51.62%) is better than 76.39% of its industry peers.
  • TWST's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for TWST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.04%
GM growth 5Y9.75%
TWST Yearly Profit, Operating, Gross MarginsTWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TWST has been increased compared to 1 year ago.
  • The number of shares outstanding for TWST has been increased compared to 5 years ago.
  • TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TWST Yearly Shares OutstandingTWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
TWST Yearly Total Debt VS Total AssetsTWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 7.20 indicates that TWST is not in any danger for bankruptcy at the moment.
  • TWST's Altman-Z score of 7.20 is fine compared to the rest of the industry. TWST outperforms 77.93% of its industry peers.
  • There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.2
ROIC/WACCN/A
WACC8.72%
TWST Yearly LT Debt VS Equity VS FCFTWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • TWST has a Current Ratio of 3.78. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.78, TWST perfoms like the industry average, outperforming 45.49% of the companies in the same industry.
  • A Quick Ratio of 3.37 indicates that TWST has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.37, TWST is in line with its industry, outperforming 42.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.78
Quick Ratio 3.37
TWST Yearly Current Assets VS Current LiabilitesTWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • TWST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.46%, which is quite impressive.
  • Looking at the last year, TWST shows a quite strong growth in Revenue. The Revenue has grown by 18.59% in the last year.
  • The Revenue has been growing by 33.11% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)38.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.66%
Revenue 1Y (TTM)18.59%
Revenue growth 3Y22.75%
Revenue growth 5Y33.11%
Sales Q2Q%16.89%

3.2 Future

  • TWST is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.25% yearly.
  • The Revenue is expected to grow by 15.32% on average over the next years. This is quite good.
EPS Next Y18.93%
EPS Next 2Y19.18%
EPS Next 3Y16.25%
EPS Next 5YN/A
Revenue Next Year15.9%
Revenue Next 2Y15.55%
Revenue Next 3Y15.69%
Revenue Next 5Y15.32%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TWST Yearly Revenue VS EstimatesTWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
TWST Yearly EPS VS EstimatesTWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • TWST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TWST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TWST Price Earnings VS Forward Price EarningsTWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TWST Per share dataTWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TWST's earnings are expected to grow with 16.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.18%
EPS Next 3Y16.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TWST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TWIST BIOSCIENCE CORP

NASDAQ:TWST (2/23/2026, 7:13:05 PM)

After market: 47.65 -0.44 (-0.91%)

48.09

-0.5 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-02
Earnings (Next)05-04
Inst Owners119.83%
Inst Owner Change1.98%
Ins Owners2.08%
Ins Owner Change6.01%
Market Cap2.95B
Revenue(TTM)391.56M
Net Income(TTM)-76.58M
Analysts84.71
Price Target48.35 (0.54%)
Short Float %20.16%
Short Ratio9.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.39%
Min EPS beat(2)-14%
Max EPS beat(2)-2.79%
EPS beat(4)1
Avg EPS beat(4)-2.91%
Min EPS beat(4)-14%
Max EPS beat(4)17.53%
EPS beat(8)4
Avg EPS beat(8)-7.26%
EPS beat(12)8
Avg EPS beat(12)0.24%
EPS beat(16)12
Avg EPS beat(16)6.24%
Revenue beat(2)1
Avg Revenue beat(2)0.3%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-1.51%
Max Revenue beat(4)0.85%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)9
Avg Revenue beat(12)1.76%
Revenue beat(16)11
Avg Revenue beat(16)1.82%
PT rev (1m)20%
PT rev (3m)22.11%
EPS NQ rev (1m)-10.81%
EPS NQ rev (3m)-13.57%
EPS NY rev (1m)-6.57%
EPS NY rev (3m)-10.63%
Revenue NQ rev (1m)1.74%
Revenue NQ rev (3m)2.13%
Revenue NY rev (1m)0.73%
Revenue NY rev (3m)-0.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.53
P/FCF N/A
P/OCF N/A
P/B 6.46
P/tB 8.17
EV/EBITDA N/A
EPS(TTM)-2.08
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-1.41
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS6.39
BVpS7.44
TBVpS5.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12%
ROE -16.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.62%
FCFM N/A
ROA(3y)-24.14%
ROA(5y)-23.35%
ROE(3y)-31.13%
ROE(5y)-29.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.04%
GM growth 5Y9.75%
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.77%
Cap/Sales 9.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.78
Quick Ratio 3.37
Altman-Z 7.2
F-Score5
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)74.54%
Cap/Depr(5y)223.62%
Cap/Sales(3y)6.8%
Cap/Sales(5y)18.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.66%
EPS Next Y18.93%
EPS Next 2Y19.18%
EPS Next 3Y16.25%
EPS Next 5YN/A
Revenue 1Y (TTM)18.59%
Revenue growth 3Y22.75%
Revenue growth 5Y33.11%
Sales Q2Q%16.89%
Revenue Next Year15.9%
Revenue Next 2Y15.55%
Revenue Next 3Y15.69%
Revenue Next 5Y15.32%
EBIT growth 1Y17.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.49%
EBIT Next 3Y26.49%
EBIT Next 5Y23.24%
FCF growth 1Y32.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.2%
OCF growth 3YN/A
OCF growth 5YN/A

TWIST BIOSCIENCE CORP / TWST FAQ

Can you provide the ChartMill fundamental rating for TWIST BIOSCIENCE CORP?

ChartMill assigns a fundamental rating of 4 / 10 to TWST.


What is the valuation status for TWST stock?

ChartMill assigns a valuation rating of 0 / 10 to TWIST BIOSCIENCE CORP (TWST). This can be considered as Overvalued.


How profitable is TWIST BIOSCIENCE CORP (TWST) stock?

TWIST BIOSCIENCE CORP (TWST) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for TWST stock?

The Earnings per Share (EPS) of TWIST BIOSCIENCE CORP (TWST) is expected to grow by 18.93% in the next year.